We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

This study has been terminated.
(Study has been put on clinical hold by FDA)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01480232
First Posted: November 28, 2011
Last Update Posted: April 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
FORUM Pharmaceuticals Inc
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
A. Eden Evins, Massachusetts General Hospital
November 23, 2011
November 28, 2011
December 15, 2016
April 6, 2017
April 6, 2017
December 2011
September 2015   (Final data collection date for primary outcome measure)
  • Effects of EVP-6124 on 7-day Point-prevalence Smoking Abstinence [ Time Frame: Week 1, 2, 4, 6, 8, 10, 12 ]
    Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) <10 ppm and/or urine cotinine <50 ng/mL.
  • Difference in Expired Carbon Monoxide (CO) Concentration From Baseline to End Point [ Time Frame: Baseline, Weeks 1, 2, 4, 6, 8, 10, 12 ]
    CO concentration was measured at every visit.
  • Effects of EVP-6124 on 7-day Point-prevalence Smoking Abstinence [ Time Frame: Weeks 1-12 ]
    Smoking abstinence is defined as a self-report of smoking no cigarettes for the past 7 days by time-line follow-back, confirmed by expired carbon monoxide (CO) <10 ppm and/or urine cotinine <50 ng/mL.
  • Difference in expired CO concentration [ Time Frame: Weeks 1-12 ]
    CO concentration over time will be plotted to determine whether there is variation in the effect of EVP-6124, using a random effect model.
Complete list of historical versions of study NCT01480232 on ClinicalTrials.gov Archive Site
  • Effects of EVP-6124 on Cognitive Performance as Measured by the Continuous Performance Test Hit Reaction Time [ Time Frame: Baseline, week 1, week 12 ]
    The Continuous Performance Test (CPT) is a measure of both vigilance/attentional control and response inhibition. During the task, subjects are required to press a button whenever a letter appears on the screen unless that letter is an 'X'. Measures of attentional control will serve as primary measure from this test. Baseline attentional impairment is associated with reduced odds of abstinence, abstinence differentially worsens performance on this measure in those with baseline attentional impairment, and NRT improves performance on a similar measure.
  • Safety and Tolerability of EVP-6124 Alone or Combined With NRT [ Time Frame: Weeks 1-12 ]
    All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements. Data was collected at every visit and was analyzed as aggregate at the end of week 12
  • Effects of EVP-6124 on Working Memory as Measured by the N-Back Task Reaction Time [ Time Frame: Baseline, week 1, week 12 ]
    This task is a standard measure that can assess working memory performance under varying levels of task demand. Subjects are presented with a stream of stimuli, and the task is to decide for each stimulus whether it matches the one presented N items before. The processing load can be varied systematically by manipulating the value of N, which is expressed with changes in accuracy and reaction time. The number of errors as well as reaction times increase monotonically with increasing levels of N. The n-back task is sensitive to nicotine administration and abstinence effects. Here we present reaction time (RT)
  • Effects of EVP-6124 on cognitive performance [ Time Frame: Weeks 1-12 ]
    Cognitive performance will be measured using the N-Back Task, Stroop Task, Cambridge Neuropsychological Test Automated Battery, Smoking Emotional Stroop Task, and the Continuous Performance Test - Conners Version. Additional testing will include nicotine craving and withdrawal assessments (Tiffany Questionnaire of Smoking Urges and Wisconsin Smoking Withdrawal Scale) and psychological efficacy assessments (Positive and Negative Affect Scale, Center for Epidemiologic Studies-Depression [CES-D] Scale, and the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire).
  • Safety and Tolerability of EVP-6124 Alone or Combined With NRT [ Time Frame: Weeks 1-14 ]
    All AEs (adverse experiences) spontaneously reported by subjects and/or observed by investigator and evaluation of physical examinations, prior and concomitant medications, clinical laboratory tests, ECGs, and vital signs measurements.
Not Provided
Not Provided
 
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence
This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Nicotine Dependence
  • Smoking Cessation
  • Drug: EVP-6124
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
  • Drug: Placebo Capsule
    One placebo capsule ingested orally daily for 12 weeks (84 days)
  • Drug: NicoDerm Patch (Active)
    One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
  • Drug: NRT Patch (Placebo)
    One NRT patch (Placebo) daily for first 6 weeks (42 days).
  • Behavioral: Brief Supportive and Behavioral Treatment
    Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
  • Experimental: EVP-6124 + NicoDerm (Active)
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: EVP-6124
    • Drug: NicoDerm Patch (Active)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Active Comparator: Placebo + NicoDerm (Active)
    One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: Placebo Capsule
    • Drug: NicoDerm Patch (Active)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Experimental: EVP-6124 + NRT Patch (Placebo)
    One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: EVP-6124
    • Drug: NRT Patch (Placebo)
    • Behavioral: Brief Supportive and Behavioral Treatment
  • Placebo Comparator: Placebo + NRT Patch (Placebo)
    One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
    Interventions:
    • Drug: Placebo Capsule
    • Drug: NRT Patch (Placebo)
    • Behavioral: Brief Supportive and Behavioral Treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
345
September 2015
September 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Self-report of smoking an average of ≥10 cigarettes/day for 6 months and expired carbon monoxide (CO) ≥10 parts per million (ppm) or urine cotinine ≥ 100 ng/mL at screening or self-report of smoking an average of 5-9 cigarettes/day for 6 months and a urine cotinine ≥30ng/ml at screening
  • Have a negative urine drug screen at screening
  • Fertile, sexually active subjects (males and females) must use an effective method of contraception from the first dose of study drug and for 3 months after the last dose of study drug
  • If female and capable of conception, must have a negative urine Human chorionic gonadotrophin (hCG) pregnancy test at screening and Day 1

Exclusion Criteria:

  • Have unstable medical illness with hospitalization for treatment likely within 6 months
  • Have life-threatening arrhythmia, cerebrovascular or cardiovascular event within 6 months of enrollment
  • Have liver function tests elevated >2.5 times the upper limit of normal range
  • Have a tumor or a seizure disorder
  • Currently using other tobacco- or nicotine-containing products and unwilling to try to quit
  • Have a 6-month history of substance use disorder other than nicotine or caffeine or major depressive disorder
  • Have a history of multiple adverse drug reactions
  • Non-response (past 3 months) to nicotine replacement therapy (NRT) >20 mg/day, bupropion >150 mg/day, or varenicline 2 mg/day for ≥4 weeks
  • Use of excluded concomitant medications
  • Hospitalization for any reason within 30 days of screening
  • Use of any investigational drug or device within 30 days of screening
  • Have clinically significant abnormal serum electrolytes
  • Have insufficiently controlled diabetes mellitus
  • Have renal insufficiency (serum creatinine >1.8 mg/dL)
  • Malignant tumor within the last 5 years, with the exception of squamous and basal cell carcinoma or cervical carcinoma in situ
  • Have a clinically significant cardiovascular abnormality on the screening EKG
  • Lifetime history of schizophrenia, bipolar disorder, post-traumatic stress disorder, bulimia, organic mental disorder, dementia, pervasive developmental disorder
  • Have untreated, clinically significant hypothyroidism or hyperthyroidism
  • Have a positive self-report of human immunodeficiency virus infection
  • Females who are pregnant or nursing
  • Any experimental drug currently or within 30 days before baseline
  • Have a serious risk of suicide
  • Have a screening electrocardiogram (ECG) with a corrected QT (QTc) interval using Bazett's formula >450 msec for males and >470 msec for females or the presence of any clinically significant cardiac abnormalities
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01480232
EVP-6124-014
1R01DA030992-01 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
A. Eden Evins, Massachusetts General Hospital
A. Eden Evins
  • FORUM Pharmaceuticals Inc
  • National Institute on Drug Abuse (NIDA)
Principal Investigator: Anne Eden Evins, MD, MPH Massachusetts General Hospital
Principal Investigator: Maurizio Fava, MD Massachusetts General Hospital
Massachusetts General Hospital
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP